Premium
Prodrug‐Based Versatile Nanomedicine for Enhancing Cancer Immunotherapy by Increasing Immunogenic Cell Death
Author(s) -
Bai Shuang,
Yang LeiLei,
Wang Yajun,
Zhang Tian,
Fu Lvqin,
Yang Shaochen,
Wan Shucheng,
Wang Shuo,
Jia Die,
Li Baosheng,
Xue Peng,
Kang Yuejun,
Sun ZhiJun,
Xu Zhigang
Publication year - 2020
Publication title -
small
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.785
H-Index - 236
eISSN - 1613-6829
pISSN - 1613-6810
DOI - 10.1002/smll.202000214
Subject(s) - tumor microenvironment , immunotherapy , prodrug , immunogenic cell death , cancer immunotherapy , immune system , cancer research , nanomedicine , chemistry , medicine , pharmacology , immunology , materials science , nanotechnology , nanoparticle
Nanoparticle‐based tumor immunotherapy has emerged to show great potential for simultaneously regulating the immunosuppressive tumor microenvironment, reducing the unpleasant side effects, and activating tumor immunity. Herein, an excipient‐free glutathione/pH dual‐responsive prodrug nanoplatform is reported for immunotherapy, simply by sequentially liberating 5‐aminolevulinic acid and immunogenically inducing doxorubicin drug molecules, which can leverage the acidity and reverse tumor microenvironment. The obtained nanoplatform effectively boosts the immune system by promoting dendritic cell maturation and reducing the number of immune suppressive immune cells, which shows the enhanced adjunctive effect of anti‐programmed cell death protein 1 therapy. Overall, the prodrug‐based immunotherapy nanoplatform may offer a reliable strategy for improving synergistic antitumor efficacy.